Skip to content

Leukocyte Dysfunction in Diabetic Patients.

Leukocyte Dysfunction in Diabetic Patients.

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01144520
Enrollment
42
Registered
2010-06-15
Start date
2010-03-31
Completion date
2018-12-31
Last updated
2021-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Brief summary

The purpose of this study is to study impairment of white blood cell function in patients with type II diabetes.

Detailed description

Leucocytes from poorly controlled diabetes exhibit aberrant chemotaxis, increased susceptibility to bacterial infection, leukotriene production, lysosomal enzyme release, proinflammatory cytokine expression and production of reactive oxygen species. Aberrant glucose concentration in diabetics affects functions of peripheral blood system as well as the immune system leading to impaired host defense. Impaired wound healing is a serious complication associated with diabetes. We hypothesized that impairment in leukocyte function results in dysfunctional inflammatory response in diabetic wounds. The proposed studies focus on characterizing mechanisms that will improve our understanding of the dysfunctional inflammatory response resulting in non-healing chronic wounds in diabetics.

Interventions

None listed

Sponsors

Sashwati Roy
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Adults ages 40-60 yrs old clinically diagnosed with Type II Diabetes * Adults ages 40-60 yrs old without Diabetes

Exclusion criteria

* Unable to provide informed consent * Pregnant Females * Therapeutically Immuno-compromised

Design outcomes

Primary

MeasureTime frameDescription
Ex vivo leukocyte function by measuring ROS productionimmediately after blood drawAfter blood draw monocytes are separated from whole blood and production of oxidants by these cells

Secondary

MeasureTime frameDescription
Ex vivo NADPH oxidase gene and protein expressionAfter blood drawGene and protein expressions are measured using Western blot and real time PCR.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026